Monitor the effective date of this S-1. Once effective, Leonite Fund can immediately begin reselling shares, likely exerting continuous downward pressure on CDIX's stock price. The discount structure incentivizes the fund to accelerate resales as the stock declines.
Executive Summary
Cardiff Lexington Corp. filed an S-1 registration statement to register up to 50,166,667 common shares for resale by Leonite Fund I, LP under a June 5, 2026 common stock purchase agreement. The agreement allows the company to direct the fund to buy up to $75 million of its common stock at a 97% discount (90% below $0.20), creating severe potential dilution of 328% of current shares. The company receives no proceeds from the resale but could draw up to $75M for working capital; however, the structure and the auditor's going-concern opinion signal material financial distress and a high risk of stock price suppression.
Key Facts
- S-1 registers up to 50,166,667 shares (166,667 commitment shares + 50,000,000 reserved future shares) for resale by Leonite Fund I, LP.
- Purchase agreement allows company to request up to $75M from the fund at a 97% discount to the lower of 5-day VWAP or 3rd-day after trade (90% if below $0.20).
- Current shares outstanding: 15,283,191; potential dilution from this facility alone is ~328%.
- Company will not receive any proceeds from the resale offering; future draws are at company's discretion but tied to depressed stock prices.
- Auditor's report includes an explanatory paragraph about the company's ability to continue as a going concern.
- All revenue is derived from a single acquired entity (Nova Ortho and Spine); financial statements were not provided in this filing.
- Multiple prior S-1/A amendments (Jan–Feb 2026) show an extended SEC review process.
Financial Impact
Potential stock-based dilution of up to 328% relative to current shares outstanding, with the fund purchasing at a 3–10% discount to market. The company could access up to $75M in aggregate but at highly dilutive terms.
Risk Factors
- Extreme dilution from equity line resales could depress share price significantly.
- Going-concern opinion indicates potential insolvency risk.
- Single-source revenue concentration (Nova Ortho and Spine) makes business vulnerable.
- Convertible notes and preferred stock overhang add further dilution pressure.
- No financial data in this filing; reliance on incorporated reports for fundamental health.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001683168-26-004763 |
| Document: cardiff_ex1003.htm | 0001683168-26-004763 |
| Document: cardiff_ex1004.htm | 0001683168-26-004763 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | 8-K | $0.1162 | awaiting T+60 | — | $0.0250 (−78.49%) |
Jun 22, 2026 18w ago | EFFECT | $1.80 $0.4899 | ▲ +72.78% | ▲ +75.00% | $0.0250 (+98.61%) |
Jun 11, 2026 19w ago | S-1 | $1.40 $0.1162 | ▲ +91.70% | ▲ +95.23% | $0.0250 (+98.21%) |
Jun 11, 2026 19w ago | 8-K | $1.40 $0.1162 | ▲ +91.70% | ▲ +95.23% | $0.0250 (+98.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers